Mercury Chemistry
镁睿化学
Mercury Chemistry (镁睿化学) is an AI-chemistry CRO — a contract research organization applying AI to chemistry — and a portfolio company of Qiming Venture Partners. In a May 2025 piece, Qiming's Kan Chen named it one of the two CRO companies the firm has backed in AI chemistry, alongside Tengmai Pharma ; a later Qiming article again listed it among the firm's leading "AI + healthcare" holdings, in the company of Insilico Medicine, Schrödinger, and Deep Principle . Beyond its positioning as an AI-chemistry CRO and the Qiming backing, elsewhere's corpus carries no further detail on its founding, team, or business specifics.
AI-generated — may contain errors, please verify.
Coverage
Qiming Venture Partners Weekly: Top 10 Portfolio Company Updates Vol. 03, Jan. 27, 2026
Join us in celebrating milestone moments for Qiming Venture Partners' portfolio companies
Qiming Venture Partners' Kan Chen: Investing in Insilico Medicine four years before OpenAI went mainstream, AIDD platform has broad prospects
After completing its investment in Insilico Medicine, Qiming Venture Partners provided the company with sustained support and substantial assistance.
Qiming Venture Partners' Kan Chen: AI's Transformation of Biomedicine Is Already Evident
In the AI era, drug discovery is taking on the characteristics of data-driven, high-throughput, automated, and intelligent processes, potentially improving success rates and lowering costs. In the near term, the necessity of experimental validation will remain unchanged; over the long run, the foundational theories of biology will stay stable. This balance between transformation and continuity is reshaping the entire landscape of pharmaceutical R&D.
